Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

THREE new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile ...

Among adults with severe asthma, those with healthy weight, overweight, obesity and severe obesity each had improvements in ...

Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the ...

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Kymera Therapeutics' Q2 2025 earnings call highlights clinical progress, Gilead and Sanofi partnerships, and financial strength, setting a strong stage ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...